Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
Viridian Therapeutics (NASDAQ: VRDN), a biopharmaceutical company specializing in treatments for serious and rare diseases, has announced its participation in two upcoming investor conferences in June 2024. The company's senior management will present at the Jefferies Global Healthcare Conference in New York on June 5 at 5:00 p.m. ET, and at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 11 at 8:40 a.m. ET. Live webcasts of each presentation will be available on the Viridian Therapeutics website, with replays accessible post-events.
- Viridian Therapeutics' participation in high-profile investor conferences like Jefferies and Goldman Sachs can boost investor confidence.
- Presentation timings ensure visibility among key investors: June 5 at Jefferies and June 11 at Goldman Sachs.
- Live webcasts and replays of the presentations offer transparency and accessibility for investors.
- The press release lacks specific details on any new data or breakthroughs to be presented, which may lead to investor skepticism.
- No direct mention of financial performance or clinical trial updates, potentially leaving investors seeking more concrete information.
-
Jefferies Global Healthcare Conference (
New York, NY ): Presentation on Wednesday, June 5, 2024, at 5:00 p.m. ET.
-
Goldman Sachs 45th Annual Global Healthcare Conference (
Miami, FL ): Presentation on Tuesday June 11, 2024, at 8:40 a.m. ET.
A live webcast of each presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcasts will be available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for VRDN-001, including two global phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate its efficacy and safety in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in
Source: Viridian Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240531086999/en/
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
When will Viridian Therapeutics present at the Jefferies Global Healthcare Conference?
What time is Viridian Therapeutics' presentation at the Goldman Sachs 45th Annual Global Healthcare Conference?
How can investors access Viridian Therapeutics' presentations?
